LABORATOIRE BOUIX SANTE : revenue, balance sheet and financial ratios

LABORATOIRE BOUIX SANTE is a French company founded 33 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in CROISSY-SUR-SEINE (78290), this company of category PME shows in 2020 a revenue of 4.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - LABORATOIRE BOUIX SANTE (SIREN 390182731)
Indicator 2023 2022 2021 2020 2018 2017 2016 2015
Revenue N/C N/C N/C 4 693 885 € N/C 2 371 607 € 1 821 598 € 2 386 940 €
Net income 14 806 € 30 789 € 174 755 € 292 082 € 193 195 € 193 195 € -155 594 € 10 921 €
EBITDA N/C N/C N/C 602 812 € N/C 241 013 € -38 882 € 71 978 €
Net margin N/C N/C N/C 6.2% N/C 8.1% -8.5% 0.5%

Revenue and income statement

In 2023, LABORATOIRE BOUIX SANTE generates positive net income of 15 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2015-2023: 11 k€ -> 15 k€.

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

14 806 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 14%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 77%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

14.355%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

76.821%

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

23.5%

Solvency indicators evolution
LABORATOIRE BOUIX SANTE

Sector positioning

Debt ratio
14.36 2023
2021
2022
2023
Q1: 0.0
Med: 5.57
Q3: 50.77
Average

In 2023, the debt ratio of LABORATOIRE BOUIX SANTE (14.36) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
76.82% 2023
2021
2022
2023
Q1: 13.47%
Med: 38.42%
Q3: 58.45%
Excellent

In 2023, the financial autonomy of LABORATOIRE BOUIX SANTE (76.8%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 752.36. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

752.362

Liquidity indicators evolution
LABORATOIRE BOUIX SANTE

Sector positioning

Liquidity ratio
752.36 2023
2021
2022
2023
Q1: 133.58
Med: 205.53
Q3: 329.15
Excellent

In 2023, the liquidity ratio of LABORATOIRE BOUIX SANTE (752.36) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
LABORATOIRE BOUIX SANTE

Positioning of LABORATOIRE BOUIX SANTE in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of LABORATOIRE BOUIX SANTE is estimated at 12 163 € (range 4 629€ - 44 419€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2023
124 transactions
4k€ 12k€ 44k€
12 163 € Range: 4 629€ - 44 419€
NAF 5 all-time

Valuation method used

Net Income Multiple
14 806 € × 0.8x = 12 163 €
Range: 4 629€ - 44 419€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare LABORATOIRE BOUIX SANTE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about LABORATOIRE BOUIX SANTE

What is the revenue of LABORATOIRE BOUIX SANTE ?

The revenue of LABORATOIRE BOUIX SANTE in 2020 is 4.7 M€.

Is LABORATOIRE BOUIX SANTE profitable?

Yes, LABORATOIRE BOUIX SANTE generated a net profit of 15 k€ in 2023.

Where is the headquarters of LABORATOIRE BOUIX SANTE ?

The headquarters of LABORATOIRE BOUIX SANTE is located in CROISSY-SUR-SEINE (78290), in the department Yvelines.

Where to find the tax return of LABORATOIRE BOUIX SANTE ?

The tax return of LABORATOIRE BOUIX SANTE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does LABORATOIRE BOUIX SANTE operate?

LABORATOIRE BOUIX SANTE operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.